Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.
Journal: Future oncology (London, England)
Published: April 07, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.
Journal: Journal for immunotherapy of cancer
Published: January 20, 2026
Dostarlimab and niraparib in primary advanced ovarian cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 11, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 18, 2024
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 24, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2024
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 21, 2023
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Journal: Gynecologic oncology
Published: April 13, 2023
Challenges of conversion from robotic surgery for vascular complications.
Journal: Journal of vascular surgery cases and innovative techniques
Published: August 21, 2022
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 23, 2021
Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells.
Journal: Cell stem cell
Published: January 04, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026